Key points from article :
Biosplice Therapeutics announced dosing of cirtuvivint in its first Phase 1b clinical trial on subjects with advanced solid tumors.
Cirtuvivint has the potential to attenuate the expression of genes critical to growth, survival, and drug resistance.
Several agents are being tested in combination with cirtuvivint in diseases including castration resistant prostate cancer (CRPC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).
This trial will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of cirtuvivint.
Administered orally once daily following a five days on, two days off treatment in combination with chemotherapy or hormonal therapy.
“Pre-clinical and published data support the combinations chosen and we have biomarkers for each of the three diseases that may be predictive of response,” - Darrin Beaupre, Chief Medical Officer, Oncology, of Biosplice.
This clinical trial was estimated to complete by December 2022.
